The OBs of glargine and detemir were found to be the most unaffordable, whereas the availability of glargine was the highest among the analog insulin in the market, indicating that a vast majority of the patients would have to buy the long-acting insulin to get their diabetes treated. The gene discussed is INS; the disease is diabetes mellitus.